Announcing OKN4395
Owkin’s Precision AI Pipeline: Advancing Oncology
[
00:37
]
Learn how Owkin’s AI drug pipeline accelerates patient impact by identifying optimal indications and sub-populations for OKN4395, a promising EP2/4 antagonist.
First published
May 23, 2024